Orly Eizenberg
14Patents
3h-index
4Co-inventors
53Inventor score
Filing activity: Aug 28, 2003 → Sep 19, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9493557B2 | Chemokine binding polypeptides for treating autoimmunity and inflammation | Chemistry; Metallurgy | 7 | Active |
| US10646465B2 | Small molecules against cancer | Emerging Cross-Sectional Technologies | 6 | Active |
| US11129824B2 | Small molecules for inhibiting chemokine activity and/or cancer cells growth | Emerging Cross-Sectional Technologies | 4 | Active |
| US11261159B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | Human Necessities | 3 | Active |
| US8383769B2 | Peptides for inhibiting chemokine binding to chemokine receptors | Human Necessities | 3 | Active |
| US8039440B2 | Peptides for inhibiting chemokine binding to chemokine receptors | Human Necessities | 2 | Active |
| US11780814B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | Human Necessities | 1 | Active |
| US10959979B2 | Small molecules against cancer | Emerging Cross-Sectional Technologies | 0 | Active |
| US9427456B2 | Peptide therapy for increasing platelet levels | Human Necessities | 0 | Active |
| US8796227B2 | Peptides for inhibiting chemokine binding to chemokine receptors | Human Necessities | 0 | Active |
| US12202803B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | Human Necessities | 0 | Active |
| US12233057B2 | Small molecules for inhibiting chemokine activity and/or cancer cells growth | Emerging Cross-Sectional Technologies | 0 | Active |
| US7488717B2 | Methods of inhibiting chemokine binding to chemokine receptors | Human Necessities | 0 | Expired |
| US8685398B2 | Chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.